WO2009084671A1 - ヒト抗α9インテグリン抗体 - Google Patents
ヒト抗α9インテグリン抗体 Download PDFInfo
- Publication number
- WO2009084671A1 WO2009084671A1 PCT/JP2008/073825 JP2008073825W WO2009084671A1 WO 2009084671 A1 WO2009084671 A1 WO 2009084671A1 JP 2008073825 W JP2008073825 W JP 2008073825W WO 2009084671 A1 WO2009084671 A1 WO 2009084671A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- antibody
- integrin
- human
- mouse
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- the present invention relates to a human anti- ⁇ 9 integrin antibody and use thereof.
- a human anti- ⁇ 9 integrin antibody that binds to a loop region designated L1 of human and mouse ⁇ 9 integrin protein, inhibits ⁇ 9 integrin-dependent cell adhesion, and has an inhibitory effect on arthritis, and the antibody fragment
- the present invention relates to the diagnosis, prevention or treatment of autoimmune diseases such as rheumatoid arthritis, immune diseases such as allergies and graft rejection, and other diseases in which ⁇ 9 integrin is involved in pathogenesis using the antibody and antibody fragment.
- Integrin is one of the cell surface glycoproteins and functions mainly as a cell adhesion to extracellular matrix (collagen, laminin, etc.) and as a receptor for immunoglobulin family members (ICAM-1, VCAM-1, etc.). It is an adhesion molecule involved in signal transmission from the extracellular matrix. Thereby, the cell receives a signal from the extracellular matrix, and differentiation, proliferation, cell death, etc. are induced. Integrins are heterodimers composed of two subunits, ⁇ chain and ⁇ chain, there are different ⁇ chains and ⁇ chains, various combinations, and 24 types of integrin superfamily. Integrin knockout mice are fatal or pathological in all subunits, suggesting that individual integrins are required to maintain life. This suggests that integrins that convey the surrounding environment to cells and promote responses are functioning in all aspects of life phenomena and are involved in various pathological conditions.
- integrins that are essential for survival are thought to play a role in pathological conditions, and there are cases where the inhibition works to improve pathological conditions.
- an inhibitor of integrin ⁇ IIb ⁇ 3 specific for platelets is approved as PCTA restenosis drug abciximab (trade name: ReoPro; Eli Lilly).
- the ⁇ 4 ⁇ 1 (VLA4) inhibitor natalizumab (trade name: Antegren; ELAN) is approved as a therapeutic agent for multiple sclerosis.
- the ⁇ v ⁇ 3 inhibitor Vitaxin (MEDIMMUNE) is currently undergoing clinical trials due to its angiogenesis inhibitory action, osteoclast activation inhibitory action, and the like.
- Integrin ⁇ 9 ⁇ 1 is expressed in macrophages, NKT cells, dendritic cells (Dendritic® cells), and neutrophils, and is said to play an important role in infiltration and adhesion of these inflammatory cells, bone resorption, and the like. Recently, the involvement of integrin ⁇ 9 ⁇ 1 has been reported in the formation of osteoclasts, suggesting the involvement in bone destruction (Non-patent Document 1). As the ligand, truncated osteopontin (N-terminal OPN), VCAM-1, Tenascin-C and the like are known. Also in clinical practice, a significant increase in integrin ⁇ 9 ⁇ 1 has been observed in the synovial tissue of rheumatoid arthritis patients (Non-patent Document 2).
- a monoclonal antibody that specifically binds to ⁇ 9 integrin protein and has an activity to inhibit ⁇ 9 integrin-dependent cell adhesion can be developed, it can be used for diagnosis, prevention or treatment of various diseases in which ⁇ 9 integrin is involved in pathogenesis. Expected to be useful.
- Non-patent Document 3 mouse monoclonal antibody Y9A2
- Mouse monoclonal antibodies 1K11, 24I11, 21C5 and 25B6 Patent Document 1
- these antibodies have been shown by in vitro experiments to be able to suppress human ⁇ 9 integrin-dependent cell adhesion, they do not have cross-reactivity with mouse or rat ⁇ 9 integrin. It is not suitable for use in experiments such as in vivo drug efficacy evaluation.
- hamster monoclonal antibodies 11L2B, 12C4'58, 18R18D and 55A2C have been reported as antibodies exhibiting a function-inhibiting action against mouse ⁇ 9 integrin.
- Patent Document 1 hamster monoclonal antibodies 11L2B, 12C4'58, 18R18D and 55A2C
- mice Even if an anti-human ⁇ 9 integrin antibody is obtained and functional evaluation is performed in vitro, if it does not show cross-reactivity with mouse or rat ⁇ 9 integrin, models of various inflammatory diseases are mice. Since most systems use rats and rats, it is difficult to evaluate the efficacy of the antibody. In addition, even if anti-mouse ⁇ 9 integrin antibody is obtained and drug efficacy is evaluated using a pathological model system of in vivo, and a therapeutic or prophylactic effect is found, if it does not show cross-reactivity with human ⁇ 9 integrin, It cannot be applied to human pathologies as an antibody drug.
- an anti-human ⁇ 9 monoclonal antibody such as Y9A2 is developed as an antibody drug based on the drug efficacy data obtained using the anti-mouse ⁇ 9 integrin antibody, it is an antibody and development product used for acquiring pharmacological data.
- a great deal of effort is required to prove equivalence with antibodies. Therefore, for example, it is desirable to have an antibody that exhibits a function-inhibiting action on both mice and humans.
- obtaining such an antibody can be said to be difficult in principle by conventional methods for immunizing mice. .
- an anti-human ⁇ 9 monoclonal antibody prepared by some technique is developed as an antibody drug to overcome such difficulties, if the antibody is an antibody derived from a non-human animal, it is administered to humans Because of its high immunogenicity, it is recognized and excluded as a foreign substance. Therefore, it is difficult to use such antibodies as therapeutic agents for diseases.
- ⁇ 9 integrin has little structural information such as three-dimensional structure, ligand binding site, and neutralizing epitope. If such information is obtained, it can be used for research on ⁇ 9 integrin and its application to medicine. It is expected that new paths will be opened and the contributions can be enormous.
- an object of the present invention is to provide a human anti- ⁇ 9 integrin antibody that has specific reactivity with both human ⁇ 9 integrin and mouse ⁇ 9 integrin and has both safety and therapeutic effects.
- the novel prevention or treatment of various diseases in which ⁇ 9 integrin is involved in pathogenesis by utilizing the anti- ⁇ 9 integrin antibody's strong anti-inflammatory action and bone destruction inhibiting action by blocking the interaction between ⁇ 9 integrin and its multiple ligands Is to provide a means.
- the present inventors prepared ⁇ 9 integrin-expressing cells and directly reacted with an antibody phage library displaying human antibodies on the cells, thereby allowing humans having specific reactivity to mouse ⁇ 9 integrin and human ⁇ 9 integrin.
- the present inventors have found that the antibodies and antibody fragments inhibit ⁇ 9 integrin-dependent cell adhesion, have a therapeutic effect on a plurality of arthritis models, and suppress osteoclast differentiation in the models. That is, the present invention has been completed by demonstrating that the antibody and the antibody fragment have both safety and therapeutic effects.
- the present invention includes the following 1) to 16) as medically or industrially useful methods and substances.
- a method for preventing or treating rheumatoid arthritis in a subject comprising the step of administering to the subject a therapeutically effective amount of the antibody or antibody fragment described in any one of 1) to 8) above.
- the human monoclonal antibody and the antibody fragment of the present invention have the variable region of a human-derived anti- ⁇ 9 integrin antibody, specific reactivity with human and mouse ⁇ 9 integrin, and inhibitory activity against ⁇ 9 integrin-dependent cell adhesion, Has an inhibitory effect on arthritis.
- the epitope was a loop region (named L1) that has not been reported in other integrin families.
- the antibody and the antibody fragment according to the present invention are fully human antibodies, they can be expected to be used as new diagnostic, preventive or therapeutic agents for various diseases involving ⁇ 9 integrin.
- the scFv display phage library can be prepared as follows. Immunoglobulin heavy (H) chain and light (L) chain cDNA is synthesized from peripheral blood B lymphocytes collected from a plurality of healthy subjects by RT-PCR. Next, various primers are combined to amplify the H chain variable region (VH) and L chain variable region (VL), and bind them together with linker DNA, thereby randomly combining VH and VL derived from healthy lymphocytes. To create a library of scFv genes. By incorporating this scFv gene into a phagemid vector (eg, pCANTAB5E), a healthy person-derived scFv display phage library consisting of about 10 8 to 10 11 clones can be constructed.
- a phagemid vector eg, pCANTAB5E
- the ⁇ 9 integrin that is an antigen can be prepared as follows. Since ⁇ 9 integrin (hereinafter also simply referred to as “ ⁇ 9”) is a membrane protein, the ⁇ 9 gene can be cloned, introduced into cultured cells, and artificially expressed on the surface of cultured cells. A cDNA library or the like may be used as a gene cloning template. In order to express it on the cell surface, it is usually necessary to have a signal sequence at the N-terminal portion. Therefore, the signal sequence inherent in ⁇ 9 may be used, or the gene region encoding mature ⁇ 9 may be used as another signal. It may be linked to an array. Regarding the antibody to be produced, it is necessary to evaluate the species specificity and the like to determine the use and possibility of the antibody. Therefore, it is desirable to obtain genes for both human ⁇ 9 and mouse ⁇ 9.
- the ⁇ 9 gene containing the signal sequence obtained as described above is cloned into an expression vector such as a pcDNA3.1 (-) vector (Invitrogen).
- a pcDNA3.1 (-) vector Invitrogen
- ⁇ 4 is said to have the highest homology with ⁇ 9. For this reason, it is desirable to perform the same operation for ⁇ 4 integrin and clone it into an expression vector for use as a control for ⁇ 9.
- the constructed expression vector is introduced into cultured cells such as CHO cells and SW480 cells by transfection using Lipofectamine 2000 (Invitrogen) or the like. Only expression cells can be selected using an expression vector marker (neomycin or the like), and the obtained cells can be used for subsequent screening and evaluation. About the expression cell, it is good to obtain the cell which shows a high expression level more stably by cloning by a limiting dilution method etc. and making it a uniform cell population.
- the library is reacted with CHO cells and subtracted, and then bound to mouse ⁇ 9-expressing CHO cells, collected and concentrated, and screened for anti- ⁇ 9 scFv display phage clones.
- an antigen not a cell itself but a membrane fraction can be prepared and used, or an antigen can be purified from a membrane fraction and used.
- the scFv of the clone thus obtained is prepared and the reactivity with ⁇ 9 expressing cells is confirmed.
- an expression method of scFv for example, it can be expressed in E. coli.
- Escherichia coli it can be expressed by functionally binding scFv to be expressed such as a commonly used useful promoter and a signal sequence for antibody secretion.
- the promoter include lacZ promoter and araB promoter.
- a signal sequence for secretion of scFv a pelB signal sequence (J. Bacterio R1987, 169: 4379-4383) may be used when expressed in the periplasm of E. coli.
- the signal sequence of g13 protein of M13 phage can also be used.
- the scFv expressed inside and outside the cell can be separated from the host and purified to homogeneity.
- scFv expressed in the pCANTAB5E system has an Etag sequence added to its C terminus and can be easily purified in a short time using affinity chromatography using an anti-Etag antibody.
- it can be purified by a combination of separation and purification methods used in ordinary proteins.
- antibodies can be separated and purified by combining column chromatography such as ultrafiltration, salting out, gel filtration / ion exchange / hydrophobic chromatography.
- the purified preparation can be analyzed for molecular morphology by HPLC gel filtration analysis or the like.
- Methods for measuring the binding activity of the obtained antibody or antibody fragment to ⁇ 9 integrin include methods such as ELISA and FACS.
- ELISA a sample containing the antibody or antibody fragment of interest, such as a culture supernatant of Escherichia coli or a purified antibody, is added to a 96-well plate in which ⁇ 9 integrin-expressing cells are immobilized directly or via a capture antibody.
- enzymes such as horseradish peroxidase (HRP) and alkaline phosphatase (AP), fluorescent substances such as fluorescein isocyanate and rhodamine, radioactive substances such as 32 P and 125 I, anti-Etag antibodies labeled with chemiluminescent substances, etc.
- HRP horseradish peroxidase
- AP alkaline phosphatase
- fluorescent substances such as fluorescein isocyanate and rhodamine
- radioactive substances such as 32 P and 125 I
- anti-Etag antibodies labeled with chemiluminescent substances etc.
- a detection reagent for example, chromogenic substrate TMB in the case of HRP labeling
- VH and VL DNA base sequences of the scFv gene of the isolated clone can be determined by the dideoxy method and the amino acid sequence can be estimated from the obtained DNA base sequence information.
- ⁇ 9-dependent cell adhesion As a method for evaluating whether or not the isolated clone has a function inhibitory activity against ⁇ 9, for example, there are the following methods using ⁇ 9-dependent cell adhesion as an index.
- RAA variant of N-terminal OPN N-terminal fragment after osteopontin is cleaved by thrombin
- ⁇ 9 ligands RGD sequence modified to RAA to suppress reaction with other integrins
- the cells are fixed and stained with Crystal violet and methanol, washed, and the dye in the adhered cells is extracted with Triton X-100, and the absorbance at a wavelength of 595 nm is measured. If the suppressive action is confirmed thereby, it is determined that the antibody has a function inhibitory activity against ⁇ 9.
- scFv is a monovalent antibody fragment, but it is known that the affinity and inhibitory effect may be greatly improved by the effect of Avidity by making it an IgG type or scFv-Fc type bivalent antibody. It has been.
- molecular forms with relatively large molecular weight, such as IgG type or scFv-Fc type have better in vivo stability and longer half-life than those with relatively small molecular weight, such as scFv. This is also well known.
- isolated clones may be evaluated by converting the molecular form to scFv-Fc type as follows.
- the scFv-Fc expression vector is constructed by PCR amplification of the scFv gene region of the isolated clone and inserting it into a mouse or human Fc fusion protein expression vector.
- mouse or human Fc fusion protein expression vectors include pFUSE-mIgG1-Fc or pFUSE-hIgG1-Fc (InvivoGen).
- a leader sequence that promotes secretory expression to the outside of the cell, the scFv gene, and a mouse or human Fc gene region are linked, and the expression is controlled by various promoters.
- the constructed scFv-Fc expression vector is introduced into cultured cells such as CHO cells using Lipofectamine® 2000 (Invitrogen) or the like. Extended culture is performed in a selective medium containing an expression vector marker (neomycin or the like), and the culture supernatant is collected and purified by Protein A column chromatography or the like. The obtained purified scFv-Fc sample may be analyzed by HPLC gel filtration, ELISA, FACS, ⁇ 9-dependent cell adhesion inhibition test, or the like, similar to scFv.
- Detection can be performed with an HRP-labeled anti-mouse IgG antibody in ELISA, and with a FITC-labeled anti-mouse IgG antibody in FACS.
- a mouse monoclonal antibody Y9A2 (CHEMICON) against human ⁇ 9 may be used as a control antibody.
- epitope analysis will be described. If the epitope of the antibody clone having the function inhibitory activity can be identified, the neutralizing epitope of ⁇ 9 can be clarified.
- Epitope analysis can be performed, for example, as follows. An ⁇ 9 amino acid substitution product is constructed, and the reactivity with the antibody is analyzed. If a change in the reactivity with the antibody is observed due to the amino acid substitution, the possibility that the substituted site is an epitope of the antibody is strongly suggested.
- amino acid substitution for example, there are methods such as exchanging the sequences of human ⁇ 9 and mouse ⁇ 9, exchanging the sequences of ⁇ 9 and ⁇ 4, or replacing the sequence of ⁇ 9 with Ala.
- the ⁇ -propeller domain located at the N-terminal part of the extracellular region is a site that interacts with the ligand as a feature common to the ⁇ chain of the integrin family (Science, 296, 151-155, 2002) Therefore, it is likely that a neutralizing epitope is present in this region. Therefore, the ⁇ propeller domain may be analyzed.
- the knowledge about the species specificity of the antibody is obtained from the analysis results so far, it can be used. For example, if there is a difference in the reactivity between human ⁇ 9 and mouse ⁇ 9, the amino acid sequence of the epitope region may be slightly different between human and mouse. Since human ⁇ 9 and mouse ⁇ 9 are highly homologous, if a site whose amino acid sequence is different between human ⁇ 9 and mouse ⁇ 9 is selected from the candidate sites to be analyzed, further candidates The site is narrowed down, and analysis can be performed efficiently.
- a fluorescent protein such as EGFP may be used as a marker for confirming the expression of the human ⁇ 9 variant.
- EGFP fluorescent protein
- the expression of ⁇ 9 can be confirmed by fluorescence, and the reactivity of the antibody according to the expression level can be evaluated. Therefore, more quantitative evaluation is possible.
- Such an ⁇ 9 or ⁇ 9-EGFP fusion amino acid substitution product is constructed by site-directed mutagenesis method or the like. They are cloned into expression vectors and introduced into cultured cells such as CHO cells. For transiently or stably expressed cell populations, the expression of wild type or modified ⁇ 9 (or ⁇ 9-EGFP) and their reactivity with the antibody can be evaluated using ELISA or FACS. . For example, when various amino acid substitutions are constructed based on ⁇ 9-EGFP and the reactivity with the antibody is analyzed by FACS, the expression level can be expressed by indicating the expression of ⁇ 9-EGFP on the horizontal axis and the reactivity with the antibody on the vertical axis. It becomes possible to discuss the reactivity with the antibody of interest.
- mouse collagen antibody-induced arthritis which is a typical arthritis model
- mouse collagen antibody-induced arthritis may be used as a mouse disease state model system.
- efficacy of each antibody clone against mouse collagen antibody-induced arthritis can be evaluated by the following procedure.
- the anti-collagen antibody cocktail is administered to mice and LPS is administered 3 days later to induce the onset of arthritis.
- scFv-Fc of the clone is intraperitoneally administered at 500, 170, 56 ⁇ g / head. Observe and score the degree of swelling of all limbs over time, and graph the transition of the average value of each group. As a result, if a scFv-Fc concentration-dependent arthritis inhibitory effect is observed, the clone is judged to have a medicinal effect on arthritis.
- mouse collagen-induced arthritis which is another typical arthritis model
- Collagen antibody-induced arthritis is known to induce an acute inflammatory response
- collagen-induced arthritis is known to cause a chronic inflammatory response via an immune response.
- efficacy of the clone against mouse collagen-induced arthritis can be evaluated by the following procedure.
- the onset of arthritis is induced by administering bovine type II collagen to mice twice at 3-week intervals. Four, six, eight, ten, and twelve days after the second administration, the clones are intraperitoneally administered with 500, 170, 56 ⁇ g / head of scFv-Fc of the clone. The degree of swelling of all limbs over time is observed and scored to evaluate whether scFv-Fc concentration-dependent arthritis suppression is observed.
- rheumatoid arthritis is a chronic inflammatory disease accompanied by joint destruction, and joint destruction deprives patients of freedom and leads to a significant decrease in QOL.
- the anti-rheumatoid arthritis drugs used to date have anti-inflammatory effects, but there are no effective anti-inflammatory effects. In the future, they have both strong anti-inflammatory effects and joint destruction-inhibiting effects. Development of a therapeutic agent for rheumatoid arthritis is desired. Therefore, for example, the inhibitory effect on osteoclast differentiation of the clone may be evaluated as follows.
- Bone marrow cells were collected from the above arthritis-induced mice, cultured in ⁇ MEM medium containing RANKL and M-CSF together with scFv-Fc of the clone, and then counted for osteoclasts (TRAP positive cells). The inhibitory effect on differentiation into bone cells is evaluated.
- the scFv-Fc is administered simultaneously with the induction of arthritis, and the next day, bone marrow cells are collected from the mouse and cultured in an ⁇ MEM medium containing RANKL and M-CSF. Are counted and evaluated.
- modification method For example, a site is identified and a specific amino acid such as Ala is substituted (for example, Current Protocols in Molecular Molecular Biology edit 1987, 5: Section 8, 1-8), random amino acid introduction methods (both can be performed by site-directed mutagenesis method), and random amino acid substitution introduction into the variable region of the antibody without specifying the site ( (for example, PCR methods and applications, 1992, 2: 28-33).
- a specific amino acid such as Ala is substituted
- random amino acid introduction methods both can be performed by site-directed mutagenesis method
- random amino acid substitution introduction into the variable region of the antibody without specifying the site for example, PCR methods and applications, 1992, 2: 28-33.
- this region may be used as a site to be modified.
- a preparation may be prepared in the molecular form of scFv or scFv-Fc, and the reactivity, function inhibitory activity, and drug efficacy may be evaluated.
- ⁇ 9 can be a preventive or therapeutic drug for diseases contributing to pathogenesis.
- the present inventors conducted epitope analysis for clone MA9-413, and performed human ⁇ 9 integrin as described in the region from 104th Arg to 122nd Asp of human ⁇ 9 integrin (SEQ ID NO: 36: Swiss-Prot AC: Q13797).
- SEQ ID NO: 37 GenBankJACCESSION: described in AJ344342
- the mouse ⁇ 9 integrin amino acid sequence numbered from the N-terminus of the amino acid sequence as 1 recognizes mainly the epitope.
- This region is a loop region for which no function or role has been reported so far in other integrin family studies, and the present inventors have designated this region as the L1 region.
- the human anti- ⁇ 9 integrin antibody and antibody fragment of the present invention recognizes an epitope formed by the L1 region of ⁇ 9 integrin and is reactive to both mouse ⁇ 9 integrin and human ⁇ 9 integrin. It has no nature.
- the antibodies and antibody fragments of the present invention having such properties are expected to be industrially applicable as novel diagnostic, prophylactic or therapeutic agents for various diseases involving ⁇ 9 integrin.
- the present invention provides a new possibility for research on ⁇ 9 integrin and by extension, the whole integrin family or application to industry by finding a new neutralizing epitope called L1 region.
- the present inventors obtain a plurality of clones MA9-418, HA9-107, HA9-143, and HA9-212, which have undergone molecular modifications to the above clone MA9-413 and have greatly improved reactivity to human ⁇ 9 integrin. succeeded in. These clones are expected to be more effective drugs than MA9-413.
- amino acid sequences of the VH chain and VL chain of the scFv clone having the above properties obtained by the present inventors and the base sequences encoding them are as follows.
- Clone MA9-413 The amino acid sequence of the VH chain of clone MA9-413 is shown in SEQ ID NO: 1.
- the amino acid sequences of CDR1-3 of the VH chain are shown in SEQ ID NOs: 2-4. That is, in the amino acid sequence of the VH chain shown in SEQ ID NO: 1, the 31st to 35th amino acid sequences are CDR1 (SEQ ID NO: 2), the 50th to 66th amino acid sequences are CDR2 (SEQ ID NO: 3), and the 99th to 115th amino acids.
- the second amino acid sequence corresponds to CDR3 (SEQ ID NO: 4).
- the base sequence of the gene encoding the VH chain is shown in SEQ ID NO: 5.
- the amino acid sequence of the VL chain of clone MA9-413 is shown in SEQ ID NO: 6.
- the amino acid sequences of CDRs 1-3 of the VL chain are shown in SEQ ID NOs: 7-9. That is, in the amino acid sequence of the VL chain shown in SEQ ID NO: 6, the 23rd to 35th amino acid sequence is CDR1 (SEQ ID NO: 7), the 51st to 57th amino acid sequence is CDR2 (SEQ ID NO: 8), and the 90th to 96th amino acids.
- the second amino acid sequence corresponds to CDR3 (SEQ ID NO: 9).
- the base sequence of the gene encoding the VL chain is shown in SEQ ID NO: 10.
- the amino acid sequence of the VH chain of clone MA9-107 is shown in SEQ ID NO: 18.
- the amino acid sequences of CDR1 to CDR3 of the VH chain are shown in SEQ ID NOs: 19 to 21, respectively. That is, in the amino acid sequence of the VH chain shown in SEQ ID NO: 18, the 31st to 35th amino acid sequences are CDR1 (SEQ ID NO: 19), the 50th to 66th amino acid sequences are CDR2 (SEQ ID NO: 20), and 99th to 115th.
- the second amino acid sequence corresponds to CDR3 (SEQ ID NO: 21).
- the base sequence of the gene encoding the VH chain is shown in SEQ ID NO: 22.
- the amino acid sequence of the VL chain of clone MA9-107 is identical to the VL chain of clone MA9-413 (SEQ ID NO: 6).
- the amino acid sequence of the VH chain of clone HA9-143 is shown in SEQ ID NO: 24.
- the amino acid sequences of CDR1 to CDR3 of the VH chain are shown in SEQ ID NOs: 25 to 27. That is, in the amino acid sequence of the VH chain shown in SEQ ID NO: 24, the 31st to 35th amino acid sequence is CDR1 (SEQ ID NO: 25), the 50th to 66th amino acid sequence is CDR2 (SEQ ID NO: 26), and the 99th to 115th amino acids.
- the second amino acid sequence corresponds to CDR3 (SEQ ID NO: 27).
- the base sequence of the gene encoding the VH chain is shown in SEQ ID NO: 28.
- the amino acid sequence of the VL chain of clone HA9-143 is the same as the VL chain of clone MA9-413 (SEQ ID NO: 6).
- Clone HA9-212 The amino acid sequence of the VH chain of clone HA9-212 is shown in SEQ ID NO: 30.
- the amino acid sequences of CDR1 to CDR3 of the VH chain are shown in SEQ ID NOs: 31 to 33. That is, in the amino acid sequence of the VH chain shown in SEQ ID NO: 30, the 31st to 35th amino acid sequence is CDR1 (SEQ ID NO: 31), the 50th to 66th amino acid sequence is CDR2 (SEQ ID NO: 32), and the 99th to 115th
- the second amino acid sequence corresponds to CDR3 (SEQ ID NO: 33).
- the base sequence of the gene encoding the VH chain is shown in SEQ ID NO: 34.
- the amino acid sequence of the VL chain of clone HA9-212 is identical to the VL chain of clone MA9-413 (SEQ ID NO: 6).
- the human anti- ⁇ 9 integrin antibody or antibody fragment of the invention comprises SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4; SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15; SEQ ID NO: 19, SEQ ID NO: 20.
- CDR1, CDR2, CDR3 heavy chain complementarity determining regions
- the human anti- ⁇ 9 integrin antibody or antibody fragment comprises a heavy chain complementarity determining region (CDR1, CDR2, CDR3) consisting of the amino acid sequences shown in SEQ ID NO: 31, SEQ ID NO: 32, and SEQ ID NO: 33, respectively.
- CDR1, CDR2, CDR3 heavy chain complementarity determining region
- the human anti- ⁇ 9 integrin antibody or antibody fragment of the present invention comprises a heavy sequence consisting of the amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 12, SEQ ID NO: 18, SEQ ID NO: 24, and SEQ ID NO: 30. It has a chain variable region (VH) and a light chain variable region (VL) consisting of the amino acid sequence shown in SEQ ID NO: 6.
- the human anti- ⁇ 9 integrin antibody or antibody fragment has a heavy chain variable region (VH) consisting of the amino acid sequence shown in SEQ ID NO: 30.
- VH chain and / or VL chain disclosed in the present invention was obtained in the form of scFv using the phage antibody method, and the evaluation was also performed in the molecular form of scFv or scFv-Fc.
- the human anti- ⁇ 9 integrin antibodies or antibody fragments of the present invention are not limited to their molecular forms.
- a complete antibody a complete molecular form in which the disclosed VH chain and / or VL chain is linked to a human immunoglobulin constant region, and as an antibody fragment, in addition to scFv and scFv-Fc, human immunoglobulin constants
- Other antibody fragments such as Fab, Fab ′ or F (ab ′) 2 combined with a part of the region, and a single chain antibody (scAb) in which scFv is bound to the constant region of the light chain of human immunoglobulin, It is included in the present invention.
- the present invention also includes a fusion antibody obtained by fusing the antibody or antibody fragment with another peptide or protein, or a polymer modifier such as polyethylene glycol. Included modified antibodies are also included.
- any single chain peptide consisting of 10 to 25 amino acids is used as the peptide linker.
- a modifying agent is bound to the thus obtained human anti- ⁇ 9 integrin antibody or antibody fragment of the present invention, a fusion antibody obtained by fusing the antibody or antibody fragment with another peptide or protein, or the antibody or antibody fragment.
- the modified antibody (hereinafter referred to as “human anti- ⁇ 9 integrin antibody etc.”) is further purified as necessary, and then formulated in accordance with a conventional method, such as autoimmune diseases such as rheumatoid arthritis, allergy, graft rejection, etc.
- ⁇ 9 integrin such as immune disease, osteoporosis, chronic obstructive pulmonary disease, cancer and the like can be used for the prevention and / or treatment of diseases related to pathogenesis.
- the human anti- ⁇ 9 integrin antibody of the present invention can be preferably used as a prophylactic / therapeutic agent for rheumatoid arthritis.
- dosage forms of these therapeutic agents can be parenterals such as injections and infusions, and are preferably administered by intravenous administration, subcutaneous administration, etc. (as therapeutic agents for autoimmune diseases) This can be applied to the case).
- carriers and additives corresponding to these dosage forms can be used within a pharmaceutically acceptable range.
- the amount of human anti- ⁇ 9 integrin antibody or the like added in the formulation varies depending on the patient's symptom level, age, dosage form of the formulation to be used, antibody binding titer, etc., for example, 0.1 mg / kg to 100 mg / Kg or so may be used.
- the present invention also provides a gene encoding the antibody of the present invention or a fragment thereof, and an expression vector containing the gene.
- the expression vector of the present invention is not particularly limited as long as it can express the gene encoding the antibody of the present invention or a fragment thereof in various prokaryotic and / or eukaryotic host cells and produce these polypeptides.
- a plasmid vector, a viral vector (for example, adenovirus, retrovirus) and the like can be mentioned.
- the expression vector of the present invention may contain a gene encoding the antibody of the present invention or a fragment thereof and a promoter operably linked to the gene.
- the promoter for expressing the polypeptide of the present invention in bacteria include Trp promoter, lac promoter, recA promoter, ⁇ PL promoter, lpp promoter, tac promoter and the like when the host is Escherichia.
- Examples of the promoter for expressing the antibody of the present invention or a fragment thereof in yeast include PH05 promoter, PGK promoter, GAP promoter, and ADH promoter.
- the host is Bacillus, SL01 promoter, SP02 promoter , PenP promoter and the like.
- the host is a eukaryotic cell such as a mammalian cell
- the CAG promoter Niwa (H. Et al., Gene, 108, 193-200, 1991)
- SV40-derived promoter SV40-derived promoter
- retrovirus promoter heat shock promoter Etc.
- the expression vector of the present invention may further contain a start codon, a stop codon, a terminator region, and a replicable unit.
- yeast, animal cells or insect cells are used as the host, the expression vector of the present invention may contain a start codon and a stop codon.
- an enhancer sequence, 5 ′ and 3 ′ untranslated regions of the gene encoding the polypeptide of the present invention, a splicing junction, a polyadenylation site, or a replicable unit may be included.
- the selection marker (For example, tetracycline, ampicillin, kanamycin) normally used according to the objective may be included.
- the present invention also provides a transformant into which the gene of the present invention has been introduced.
- a transformant can be produced, for example, by transforming a host cell with the expression vector of the present invention.
- the host cell used for the preparation of the transformant is not particularly limited as long as it is compatible with the above expression vector and can be transformed.
- Natural cells or artificially used usually in the technical field of the present invention can be used. Examples include various cells such as established cells (for example, bacteria (Escherichia, Bacillus), yeasts (Saccharomyces, Pichia, etc.), animal cells, insect cells (eg, Sf9), etc.). Transformation can be performed by a method known per se.
- the present invention also provides a method for producing the antibody of the present invention or a fragment thereof comprising expressing the gene of the present invention in a host cell, that is, using such a transformant.
- the transformant can be cultured in a nutrient medium.
- the nutrient medium preferably contains a carbon source, an inorganic nitrogen source or an organic nitrogen source necessary for the growth of the transformant.
- the carbon source include glucose, dextran, soluble starch, and sucrose.
- the inorganic or organic nitrogen source include ammonium salts, nitrates, amino acids, corn steep liquor, peptone, casein, meat extract, large extract, and the like. Examples include soybean cake, potato extract and the like.
- nutrients for example, inorganic salts (for example, calcium chloride, sodium dihydrogen phosphate, magnesium chloride), vitamins, antibiotics (for example, tetracycline, neomycin, ampicillin, kanamycin, etc.)
- inorganic salts for example, calcium chloride, sodium dihydrogen phosphate, magnesium chloride
- antibiotics for example, tetracycline, neomycin, ampicillin, kanamycin, etc.
- the culture of the transformant is performed by a method known per se.
- the culture conditions such as temperature, medium pH and culture time are appropriately selected.
- the medium includes MEM medium (Science, Vol. 122, p. 501, 1952) containing about 5-20% fetal bovine serum, DMEM medium (Virology, Vol. 8, p. 396, 1959), RPMI 1640 medium (J. Am. Med. Assoc., Vol. 199, p. 519, 1967), 199 medium (proc. Soc. Exp. Biol. Med., Vol. 73, p. 1). , 1950) or the like.
- the pH of the medium is preferably about 6 to 8, and the culture is usually carried out at about 30 to 40 ° C. for about 15 to 72 hours, and if necessary, aeration and agitation can be performed.
- the host is an insect cell, for example, Grace's medium containing fetal bovine serum (Proc. Natl. Acad. Sci. USA, Vol. 82, p. 8404, 1985) and the like can be mentioned, and its pH is about 5-8. Is preferred.
- the culture is usually carried out at about 20 to 40 ° C. for 15 to 100 hours, and if necessary, aeration or agitation can be performed.
- a liquid medium containing the above nutrient source is suitable.
- a medium having a pH of 5 to 8 is preferable.
- the host is E. coli.
- preferred media include LB medium, M9 medium (Miller et al., Exp. Mol. Genet, Cold Spring Harbor Laboratory, p. 431, 1972) and the like.
- the culture can be performed usually at 14 to 43 ° C. for about 3 to 24 hours with aeration and agitation, if necessary.
- the treatment can be performed usually at 30 to 40 ° C.
- examples of the medium include Burkholder minimum medium (Bostian, Proc. Natl. Acad. Sci. USA, Vol. 77, p. 4505, 1980), and the pH is 5 to 8. desirable.
- the culture is usually carried out at about 20 to 35 ° C. for about 14 to 144 hours, and if necessary, aeration or agitation can be performed.
- the antibody of the present invention or a fragment thereof can be recovered from the transformant as described above, and preferably isolated and purified from the transformant.
- Isolation and purification methods include, for example, methods using solubility such as salting out, solvent precipitation, dialysis, ultrafiltration, gel filtration, sodium dodecyl sulfate-polyacrylamide gel electrophoresis and other methods utilizing molecular weight differences, Methods using charges such as ion exchange chromatography and hydroxylapatite chromatography, methods using specific affinity such as affinity chromatography, methods using hydrophobic differences such as reversed-phase high-performance liquid chromatography, isoelectricity Examples thereof include a method using a difference in isoelectric point such as point electrophoresis.
- Example 1 Preparation of antigen Using the human cDNA library as a template, the main domain region of the human ⁇ 9 integrin gene and the signal sequence region of the human ⁇ 5 integrin gene were cloned.
- a human ⁇ 9 expression vector was constructed by ligating the signal sequence region of the human ⁇ 5 integrin gene and the main domain region of the human ⁇ 9 integrin gene and incorporating it into the pcDNA3.1 ( ⁇ ) vector (Invitrogen).
- mouse cDNA library As a template, the full length of mouse ⁇ 9 integrin gene was cloned and incorporated into pcDNA3.1 (+) vector (Invitrogen) to construct a mouse ⁇ 9 expression vector.
- human ⁇ 4 integrin and mouse ⁇ 4 integrin were also cloned by the following procedure.
- the full length of the human ⁇ 4 integrin gene was cloned and incorporated into a pcDNA3.1 (+) vector (Invitrogen) to construct a human ⁇ 4 expression vector.
- the full length of the mouse ⁇ 4 integrin gene was cloned and incorporated into a pcDNA3.1 (+) vector (Invitrogen) to construct a mouse ⁇ 4 expression vector.
- mouse ⁇ 9 integrin expression vector and mouse ⁇ 4 integrin expression vector were introduced into CHO cells, respectively, and mouse ⁇ 9 integrin expression cells (hereinafter referred to as CHO / m ⁇ 9) and mouse ⁇ 4 integrin expression cells (hereinafter referred to as CHO / m ⁇ 4). Each was established.
- human ⁇ 9 integrin expression vector and mouse ⁇ 9 integrin expression vector were introduced into SW480 cells, respectively, and human ⁇ 9 integrin expression cells (hereinafter referred to as SW480 / h ⁇ 9) and mouse ⁇ 9 integrin expression cells (hereinafter referred to as SW480 / m ⁇ 9). ) was established. These various integrin-expressing cells were used for subsequent screening and evaluation.
- Example 2 Construction of phage library from healthy subjects >> Based on the method reported by JD Marks et al. (J. Mol. Biol., 222: 581-597, 1991), a phage library was constructed using lymphocytes from peripheral blood derived from 20 healthy subjects as starting materials. .
- the constructed VH ( ⁇ ) -V ⁇ , VH ( ⁇ ) -V ⁇ , VH ( ⁇ ) -V ⁇ , and VH ( ⁇ ) -V ⁇ sub-libraries are 1.1 ⁇ 10 8 , 2.1 ⁇ 10 8 , and 8.4 ⁇ 10 7, respectively. It was evaluated to have a diversity of 5.3 ⁇ 10 7 clones.
- Example 3 Screening using ⁇ 9 integrin-expressing cells >> A specific antibody against ⁇ 9 was prepared according to the following procedure. First, a monoclonal antibody having a function inhibitory activity was constructed targeting mouse ⁇ 9, and the presence or absence of a drug effect was evaluated using a mouse disease state model system. First, subtraction of the phage display library was performed using the parent strain, CHO cells, and then reacted with CHO / m ⁇ 9. The reaction was performed for 1 hour and washed 3 times with 1% BSA / PBS. The washed cell fraction was suspended in 10 mM HCl and incubated for 10 minutes to elute the phage.
- the eluate was neutralized by mixing with 1M Tris-HCl (pH 7.5), and then infected with TG1 to amplify the phage. This panning was performed for 4 rounds, and a phage clone MA9-413 that specifically reacts with mouse ⁇ 9 was isolated.
- Example 4 Analysis of reactivity of phage antibody by ELISA
- the reactivity of MA9-413 phage antibody to ⁇ 9 was analyzed by Cell ELISA.
- CHO / m ⁇ 9 and CHO were seeded at 2 ⁇ 10 4 cells / 100 ⁇ L / well in a 96-well plate (costar) and cultured overnight at 37 ° C. and 5% CO 2 .
- the medium was aspirated and washed with PBS, and then reacted with a phage antibody diluted with 1% BSA / PBS.
- Detection was performed by combining horseradish peroxidase (HRP) -labeled anti-M13 antibody (Amersham) and TMB (SIGMA). Absorbance at wavelengths of 450 nm and 650 nm was measured using a microplate reader (Molecular Devices). The result is shown in FIG. Since ⁇ 9-specific reactivity of MA9-413 was confirmed, the subsequent analysis was performed.
- Example 5 Sequence analysis of clone >> The DNA base sequences of VH and VL of the scFv gene of the isolated clone were determined using CEQ DTCS Quick Start Kit (BECKMAN COULTER). The amino acid sequence was estimated based on the obtained DNA base sequence information.
- Example 6 Expression and purification of scFv Plasmid DNA was recovered from the specific clone MA9-413 and transformed into E. coli JM83 according to a conventional method.
- the Escherichia coli was pre-cultured overnight in 2 ⁇ YT medium containing 2% glucose and 100 ⁇ g / mL ampicillin, and partly transplanted into SB medium containing 2% glucose and 100 ⁇ g / mL ampicillin for main culture.
- IPTG was added to a final concentration of 1 mM, and cultured for 3 hours to induce scFv expression.
- the cells were collected by centrifugation, suspended in a 100 mM Tris-HCl solution (pH 7.4) containing 20% Sucrose and 10 mM EDTA, and the cells were allowed to stand in ice for 30 minutes. Subsequently, the mixture was centrifuged at 8,900 ⁇ g for 30 minutes, the supernatant was collected, and the fraction obtained after filtration through a 0.45 ⁇ m filter was used as the periplasm fraction.
- scFv was purified by SP column chromatography (Amersham) or RPAS Purification Module (Amersham) according to a conventional method, and the resulting eluted fraction was dialyzed against PBS to obtain a scFv purified sample.
- Example 7 Reactivity analysis of scFv by ELISA
- the scFv purified product prepared in Example 6 was analyzed for reactivity against ⁇ 9 by Cell ELISA.
- an HRP-labeled anti-Etag antibody (Amersham) was used, and the others were performed under the same conditions as in Example 4. As a result, as shown in FIG. 2, concentration-dependent and specific reactivity was confirmed.
- Example 8 Evaluation of scFv's ability to inhibit ⁇ 9-dependent cell adhesion >> Whether MA9-413 scFv can inhibit ⁇ 9-dependent cell adhesion was evaluated by the following method.
- An N-terminal OPN variant OPN variant in which the RGD sequence was altered to RAA
- SW480 / m ⁇ 9 was subsequently added and incubated at 37 ° C. for 1 hour.
- the cells were fixed and stained with Crystal violet and methanol, washed, the dye in the adhered cells was extracted with Triton X-100, and the absorbance at a wavelength of 595 nm was measured.
- FIG. 3 a concentration-dependent inhibitory action was observed, confirming that MA9-413 has a function inhibitory activity against mouse ⁇ 9.
- Example 9 Construction of scFv-Fc expression vector
- scFv-Fc was converted to a molecular form.
- the scFv-Fc expression vector shown in FIG. 4 was constructed by PCR amplification of the scFv gene region of MA9-413 and inserting it into the SalI site and BamHI site of the mouse Fc fusion protein expression vector.
- a leader sequence that promotes extracellular secretion, the scFv gene, and a gene encoding the Fc region of mouse IgG1 are linked, and its expression is controlled by the CAG promoter.
- this vector has a neomycin resistance gene and an ampicillin resistance gene as drug resistance genes.
- Example 10 Expression and purification of scFv-Fc >> Using Lipofectamine 2000 (Invitrogen), the constructed scFv-Fc expression vector was introduced into the CHO-DG44 strain. Culturing was performed in ⁇ -MEM medium (Invitrogen) or EX-CELL302 medium (Nichirei Bioscience) containing 500 ⁇ g / mL neomycin and 10% bovine serum, and the culture supernatant was collected. Affinity purification was performed by Protein A column chromatography according to a conventional method, followed by dialysis with PBS. The obtained scFv-Fc solution was used as a purified sample.
- Example 11 Reactivity analysis of scFv-Fc by ELISA >> The reactivity of MA9-413 scFv-Fc to mouse ⁇ 9 and human ⁇ 9 was analyzed by Cell ELISA. SW480 / m ⁇ 9, SW480 / h ⁇ 9 and SW480 are used as antigens, 1% BSA / PBS containing 5% FBS is used as a diluent, and HRP-labeled anti-mouse IgG antibody (ZYMED) is used for detection. The same conditions were used. As a result, as shown in FIG. 5, concentration-dependent and specific reactivity to mouse ⁇ 9 and human ⁇ 9 was confirmed.
- MA9-413 is an antibody clone having a novel reactivity that has not been reported so far, and can recognize both mouse ⁇ 9 and human ⁇ 9.
- Example 12 Reactivity analysis of scFv-Fc by flow cytometry >> Furthermore, the reactivity of MA9-413 scFv-Fc was evaluated by flow cytometry. When MA9-413 scFv-Fc was reacted with each of SW480, SW480 / m ⁇ 9 and SW480 / h ⁇ 9 and subjected to flow cytometry analysis, reactivity to mouse ⁇ 9 and human ⁇ 9 was confirmed. Moreover, although the reactivity was similarly evaluated with respect to each of CHO and CHO / m ⁇ 4, reactivity to mouse ⁇ 4 was not confirmed (FIG. 6). From these results, it was confirmed that MA9-413 scFv-Fc reacted with high specificity to mouse and human ⁇ 9.
- Example 13 Evaluation of scFv-Fc's ability to inhibit ⁇ 9-dependent cell adhesion >> It was evaluated whether MA9-413 scFv-Fc can inhibit mouse ⁇ 9 and human ⁇ 9-dependent cell adhesion.
- the ligand is OPN
- SW480 / m ⁇ 9 or SW480 / h ⁇ 9 was used, and the others were performed under the same conditions as in Example 8.
- cell adhesion when the ligand was VCAM-1 was evaluated by the following method. Mouse VCAM-1 / Fc was immobilized on a plate and blocked. The cells were SW480 / m ⁇ 9, and other conditions were the same as in Example 8.
- FIG. 7 a concentration-dependent inhibitory action was observed in all cases, MA9-413 has a function inhibitory activity against mouse ⁇ 9 and human ⁇ 9, and the ligand is OPN. It was shown that VCAM-1 can work in the same way.
- Example 14 Epitope analysis of MA9-413 >> For the purpose of identifying epitopes for MA9-413, which has reactivity not only in mouse ⁇ 9 and human ⁇ 9, but also exhibits functional inhibitory activity against both, and has no properties reported so far. The following analysis was performed. As a feature common to the ⁇ chain of the integrin family, the ⁇ propeller domain located in the N-terminal part of the extracellular region is said to be an interaction site with a ligand (Science, 296, 151-155, 2002). Therefore, it was first hypothesized that neutralizing epitopes exist within this region.
- R2 and R4 are important for ligand binding among repeat parts (corresponding to loop regions) called R1 to R5 in the ⁇ propeller domain, and Results have shown that R2, R3a and R3c can be neutralizing epitopes (Proc. Natl. Acad. Sci. USA, 94, 7198-7203, 1997). From these facts, it was considered that the epitope of MA9-413 is also likely to be a loop region.
- EGFP is used as a marker for confirming the expression of a human ⁇ 9 variant
- a human ⁇ 9-EGFP fusion (hereinafter referred to as h ⁇ 9-EGFP) in which EGFP is fused to the C-terminus (cytoplasmic region) of human ⁇ 9. ) Gene was constructed.
- the EGFP gene was amplified by the PCR method using the pEGFP-N1 vector (Clontech) as a template, and further assembly-PCR was performed to link with the human ⁇ 9 gene. Using the restriction enzyme cleavage site, it was incorporated into the human ⁇ 9 expression vector described in Example 1 to construct an h ⁇ 9-EGFP expression vector.
- the modified product (hereinafter referred to as h ⁇ 9 / mR4-EGFP), the modified product in which 286th Gly is substituted with Ala for R5 (hereinafter referred to as h ⁇ 9 / mR5-EGFP), and the 77th Lys for L1 Modified with Arg, 78th Asn as Thr, 81st Thr as Ala, 82nd Ser as Pro, and 89th Glu as Gly (hereinafter referred to as h ⁇ 9 / mL1-EGFP) was constructed by site-directed mutagenesis method.
- h ⁇ 4 / 9-EGFP a variant in which the entire ⁇ propeller domain is replaced with the ⁇ propeller domain of human ⁇ 4 (hereinafter referred to as h ⁇ 4 / 9-EGFP) is as follows. And built. Since the region between the restriction enzyme BlpI site and the StuI site of the human ⁇ 9 gene corresponds to the ⁇ -propeller domain, the human ⁇ 4 gene region corresponding to that region was added to the human ⁇ 4 gene using primers added with the BlpI site and the StuI site, respectively. PCR amplification was carried out using the expression vector as a template, digested with BlpI and StuI, and then replaced with the region between the BlpI site and the StuI site of the human ⁇ 9-EGFP fusion expression vector.
- the MA9-413 scFv-Fc reaction pattern is different only in h ⁇ 9 / mL1-EGFP, and the reactivity per expression level is higher compared to h ⁇ 9-EGFP and other variants.
- h ⁇ 9 / mL1-EGFP is a variant in which the L1 region is substituted from the human sequence to the mouse sequence, and MA9-413 reacts more strongly with mouse ⁇ 9 than with human ⁇ 9. This strongly suggests that it is the L1 region.
- Example 15 Evaluation 1 of scFv-Fc efficacy against mouse arthritis model >> It was examined whether scFv-Fc of MA9-413, in which not only the reaction pattern but also the epitope was a novel region, could be effective against a mouse arthritis model. First, the effect on mouse collagen antibody-induced arthritis, one of representative arthritis models, was examined. Anti-collagen antibody cocktail was administered to mice and LPS was administered 3 days later to induce the development of arthritis. On the day and 3 days after LPS administration, MA9-413 scFv-Fc was intraperitoneally administered at 500, 170, 56 ⁇ g / head, and control mouse antibody was intraperitoneally administered at 500 ⁇ g / head (4 to 8 mice in each group).
- Example 16 ScFv-Fc efficacy evaluation 2 for mouse arthritis model >> Next, it was evaluated whether MA9-413 scFv-Fc shows efficacy against mouse collagen-induced arthritis, which is another typical arthritis model. It is known that the collagen antibody-induced arthritis of Example 15 induces an acute inflammatory response, whereas the collagen-induced arthritis causes a chronic inflammatory response. Onset of arthritis was induced by administering bovine type II collagen to mice twice at 3-week intervals.
- Example 17 Evaluation of drug efficacy of scFv-Fc for osteoclast differentiation >> Furthermore, the effect on osteoclast differentiation in an arthritis model was examined.
- bone marrow cells were collected from the femur of the mouse the day after administration of LPS causing arthritis, and RANKL (final concentration 30 ng / mL) and M-CSF (final concentration 100 ng).
- osteoclast differentiation was induced by culturing in an ⁇ MEM medium containing (/ mL). The culture change was performed once on the third day after the start.
- MA9-413 has an action of strongly suppressing both inflammatory reactions in the acute phase and the chronic phase.
- the results of Example 17 above strongly suggested that MA9-413 has an anti-inflammatory effect as well as a joint destruction-inhibiting action under inflammation. Therefore, it is expected that this clone can be used as a drug superior to conventional drugs for treating or preventing human arthritis.
- Example 18 Affinity improvement of MA9-413 Since MA9-413 is an antibody that reacts more strongly with mouse ⁇ 9 than with human ⁇ 9, there is a possibility that the affinity is not sufficient to aim at application to human arthritis. Therefore, an attempt was made to improve affinity by molecular modification of MA9-413. In many cases, the CDR3 region of VH contributes most strongly to antigen recognition among antibody variable regions.
- the sequence of CDR3 of VH of MA9-413 is as shown in SEQ ID NO: 4, but a Tyr cluster is characteristically arranged.
- a modified scFv in which the 108th Tyr is replaced with Ala (hereinafter referred to as MA9-418) and a modified scFv in which the 109th Tyr is replaced with Ala ( (Hereinafter referred to as MA9-419) was constructed by the site-directed mutagenesis method.
- MA9-418 showed improved reactivity to mouse and human ⁇ 9 compared to MA9-413, and MA9-419 responded to mouse and human ⁇ 9. Sex was almost lost. From these results, substitution of the 108th Tyr with an optimal amino acid improves the reactivity to ⁇ 9, and the 109th Tyr is essential for antigen recognition, so substitution with other amino acids is not desirable. It has been suggested.
- Example 19 Expression and purification of scFv
- the plasmid DNA host was changed to E. coli strain JM83, and scFv expression and purification were performed.
- Expression of scFv by culturing E. coli transformant in 2 ⁇ YT medium containing 2% glucose and 100 ⁇ g / mL ampicillin, adding IPTG to a final concentration of 1 mM in the logarithmic growth phase, and culturing overnight Induced.
- the cells were collected, suspended in a 100 mM Tris-HCl solution (pH 7.4) containing 20% Sucrose and 10 mM EDTA, and the cells were allowed to stand in ice for 30 minutes. Subsequently, the mixture was centrifuged at 8,900 ⁇ g for 30 minutes, the supernatant was collected, and the fraction obtained after filtration through a 0.45 ⁇ m filter was used as the periplasm fraction.
- scFv was purified by RPASPurification Module (Amersham) according to a conventional method, and the obtained elution fraction was dialyzed against PBS to obtain a purified scFv preparation.
- the reactivity of the purified scFv was analyzed by Cell ELISA in the same manner as in Example 11 except that an HRP-labeled anti-Etag antibody (Amersham) was used for detection.
- an HRP-labeled anti-Etag antibody Amersham
- FIG. 15 compared to MA9-413, MA9-418, HA9-107, HA9-143 and HA9-212 have improved reactivity to human ⁇ 9, especially HA9-212. The degree was remarkable.
- Example 20 Construction, expression and purification of scFv-Fc
- the scFv-Fc gene was constructed in the same manner as in Example 9 for MA9-418, HA9-107, HA9-143, and HA9-212.
- the expression of scFv-Fc was performed by transient expression using freestyle 293-F cells (Invitrogen) as a host. Gene transfer was performed using 293fectin reagent (Invitrogen), and after culturing for 2 to 3 days in a freestyle 293 expression medium (Invitrogen), the culture supernatant was collected by centrifugation and 0.22 ⁇ m filter filtration. Purification was performed according to a conventional method using Protein A column chromatography.
- the scFv-Fc solution obtained after PBS dialysis was used as a purified sample.
- the reactivity of the prepared scFv-Fc purified product to mouse ⁇ 9 and human ⁇ 9 was analyzed by Cell ELISA in the same manner as in Example 11. As a result, as shown in FIG. 16, the reactivity of MA9-418, HA9-107, HA9-143, and HA9-212 to human ⁇ 9 was improved compared to MA9-413.
- Example 21 Epitope analysis of variant clones >> In order to examine whether MA9-418, HA9-107, HA9-143, and HA9-212 recognize the ⁇ 9 L1 region in the same manner as MA9-413, the following examination was performed. In the Cell ELISA performed in the same manner as in Example 4 with the MA9-413 phage antibody at a constant concentration, each variant scFv-Fc was serially diluted and added simultaneously with the sample, so that the MA9-413 phage antibody was added. It was evaluated whether or not competitive inhibition was applied. As a result, as shown in FIG. 17, it was confirmed that competitive inhibition was applied in a concentration-dependent manner. Therefore, it was strongly suggested that MA9-418, HA9-107, HA9-143, and HA9-212 also recognize the ⁇ 1 L1 region as in MA9-413.
- Example 22 Evaluation of ⁇ 9-dependent cell adhesion inhibitory ability of modified clones >> The scFv-Fc of each variant clone was evaluated in the same manner as in Example 13 for its ability to inhibit human ⁇ 9 and mouse ⁇ 9-dependent cell adhesion. Table 1 summarizes the IC50 values. All of the mutant clones were confirmed to have a strong inhibitory ability against human ⁇ 9 compared to the original MA9-413. In particular, HA9-212 had about 1000 times the inhibitory ability against human ⁇ 9 compared to MA9-413.
- Example 23 Production and preparation of IgG With regard to clone HA9-212 that showed the highest reactivity with human ⁇ 9, the reactivity of IgG in the molecular form was examined.
- IgG gene construction was carried out by the following procedure. First, the VH gene region of HA9-212 was PCR amplified and inserted into the cloning site of a human H chain expression vector. In this vector, a leader sequence that promotes secretory expression to the outside of the cell, the VH gene, and the human IgG1 constant region gene are linked, and the expression is controlled by the CAG promoter. Moreover, this vector has a neomycin resistance gene and an ampicillin resistance gene as drug resistance genes.
- the VL gene region of MA9-212 was PCR amplified and inserted into the cloning site of the human L chain expression vector.
- a leader sequence that promotes secretory expression to the outside of the cell, a VL gene, and a human ⁇ chain constant region gene are linked, and the expression is controlled by the CAG promoter.
- This vector has a dhfr gene and an ampicillin resistance gene.
- IgG was expressed by transient expression using COS-7 cells and freestyle 293-F cells (Invitrogen) as hosts.
- COS-7 cells use Lipofectamine 2000 (Invitrogen), and for Freestyle 293-F cells, use 293 fectin reagent (Invitrogen) for gene transfer. After culturing for 2-3 days, culture supernatant was recovered by centrifugation and 0.22 ⁇ m filter filtration.
- Example 24 IgG reactivity analysis
- the IgG expression level in the culture supernatant was quantified by human IgG quantitative ELISA, and the reactivity to human ⁇ 9 and mouse ⁇ 9 at each IgG concentration was analyzed by Cell ELISA.
- an HRP-labeled anti-human IgG (Fc) antibody (American Qualex) was used, and the other conditions were the same as in Example 11.
- Fc horseradishin-labeled anti-human IgG
- FIG. 18 concentration-dependent and specific reactivity to human ⁇ 9 and mouse ⁇ 9 was confirmed, and particularly strong reactivity to human ⁇ 9 was shown. From these results, it was confirmed that HA9-212 exhibits reactivity with ⁇ 9 even in the molecular form of IgG.
- MA9-418, HA9-107, HA9-143 and HA9-212 obtained by modifying MA9-413 react with both mouse ⁇ 9 and human ⁇ 9 possessed by MA9-413. It was confirmed that the reactivity and inhibitory ability to human ⁇ 9 were greatly improved while maintaining the property of recognizing the L1 region. Furthermore, HA9-212 showed strong reactivity with human ⁇ 9 even in the molecular form of IgG. From these facts, the MA9-413 variant is highly expected to be useful as a drug for the treatment or prevention of human arthritis superior to MA9-413.
- the human monoclonal antibody and the antibody fragment of the present invention have the variable region of a human-derived anti- ⁇ 9 integrin antibody, specific reactivity with human and mouse ⁇ 9 integrin, and inhibitory activity against ⁇ 9 integrin-dependent cell adhesion, Since it has an inhibitory action against arthritis, it can be expected to be used as a new diagnostic, preventive or therapeutic agent for various diseases involving ⁇ 9 integrin.
- This application is based on Japanese Patent Application No. 2007-340203 filed in Japan (filing date: December 28, 2007), the contents of which are incorporated in full herein.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
1)ヒトα9インテグリン及びマウスα9インテグリンを認識し、該α9インテグリンとリガンドとの相互作用を阻害する、ヒト抗α9インテグリン抗体または抗体フラグメント。
2)ヒトα9インテグリン(配列番号36)の104番目のArgから122番目のAspまでの領域が主として構成するエピトープ、及びマウスα9インテグリン(配列番号37)の105番目のArgから123番目のAspまでの領域が主として構成するエピトープを認識する、上記1)に記載の抗体または抗体フラグメント。
3)以下の配列番号に各々示されるアミノ酸配列からなる(a)重鎖相補性決定領域及び(b)軽鎖相補性決定領域(CDR1、CDR2、CDR3)を有する、上記1)または2)に記載の抗体または抗体フラグメント。
(a)重鎖相補性決定領域CDR1、CDR2、CDR3
配列番号2、配列番号3、配列番号4;
配列番号13、配列番号14、配列番号15;
配列番号19、配列番号20、配列番号21;
配列番号25、配列番号26、配列番号27;または
配列番号31、配列番号32、配列番号33;
(b)軽鎖相補性決定領域CDR1、CDR2、CDR3
配列番号7、配列番号8、配列番号9
4)配列番号31、配列番号32、配列番号33に各々示されるアミノ酸配列からなる重鎖相補性決定領域CDR1、CDR2、CDR3を有する、上記3)に記載の抗体または抗体フラグメント。
5)配列番号1、配列番号12、配列番号18、配列番号24、配列番号30のいずれかに示されるアミノ酸配列からなる重鎖可変領域、及び配列番号6に示されるアミノ酸配列からなる軽鎖可変領域を有する、上記1)または2)に記載の抗体または抗体フラグメント。
6)配列番号30に示されるアミノ酸配列からなる重鎖可変領域を有する、上記5)に記載の抗体または抗体フラグメント。
7)当該抗体が、完全抗体である上記1)から6)のいずれかに記載のヒト抗α9インテグリン抗体。
8)当該抗体フラグメントが、scFvまたはscFv-Fcである上記1)から6)のいずれかに記載のヒト抗α9インテグリン抗体フラグメント。
9)上記1)から8)のいずれかに記載の抗体または抗体フラグメントをコードする遺伝子。
10)上記9)に記載の遺伝子を含む組換え発現ベクター。
11)上記9)に記載の遺伝子が導入された形質転換体。
12)上記9)に記載の遺伝子を宿主に発現させることによって、ヒト抗α9インテグリン抗体または抗体フラグメントを生産する方法。
13)上記1)から8)のいずれかに記載の抗体または抗体フラグメントを含む、関節リウマチの予防または治療剤。
14)上記1)から8)のいずれかに記載の抗体または抗体フラグメントの治療有効量を対象に投与する工程を包含する、該対象における関節リウマチを予防または治療する方法。
15)関節リウマチの予防または治療剤の製造における、上記1)から8)のいずれかに記載の抗体または抗体フラグメントの使用。
16)関節リウマチを予防または治療するための、上記1)から8)のいずれかに記載の抗体または抗体フラグメント。
scFvディスプレイファージライブラリーは、以下のようにして作製することができる。複数の健常者から採取した末梢血Bリンパ球より、RT-PCR法にて免疫グロブリン重(H)鎖、軽(L)鎖cDNAを合成する。次に各種プライマーを組み合わせて、H鎖可変領域(VH)とL鎖可変領域(VL)を増幅させ、両者をlinker DNAで結合させることにより、健常者リンパ球由来のVHとVLのランダムな組み合わせによるscFv遺伝子のライブラリーが作製される。このscFv遺伝子をファージミドベクター(例、pCANTAB5E)に組込み、約108~1011クローンからなる健常者由来scFvディスプレイファージライブラリーを構築することができる。
α9インテグリン(以下、単に「α9」ともいう)は膜蛋白質であるため、α9遺伝子をクローニングして培養細胞に遺伝子導入を行い、人為的に培養細胞表面に発現させることができる。遺伝子クローニングの鋳型としては、cDNA library等を用いるとよい。細胞表面に発現させるためには、通常N末端部分にシグナル配列が存在する必要があるので、α9が本来有するシグナル配列を利用してもよいし、成熟型α9をコードする遺伝子領域を他のシグナル配列と連結させてもよい。作製する抗体については、種特異性等を評価し、抗体の用途や可能性を見極めることが必要であるため、遺伝子の取得はヒトα9とマウスα9の両方について行うのが望ましい。
機能阻害活性を有する抗体クローンのエピトープを同定できれば、α9の中和エピトープを明らかにすることができる。エピトープの解析は、例えば以下のようにして行うことができる。α9のアミノ酸置換体を構築して、当該抗体との反応性を解析する。アミノ酸置換により、抗体との反応性に変化が認められれば、置換した部位が抗体のエピトープである可能性が強く示唆される。アミノ酸置換の方法としては、例えば、ヒトα9とマウスα9の配列を入れ替える、α9とα4の配列を入れ替える、或いはα9の配列をAlaに置換する等の方法がある。
α9については炎症への関与が強く示唆されていることから、マウス病態モデル系としては、代表的な関節炎モデルであるマウスコラーゲン抗体誘導関節炎等を用いるとよい。例えば以下のような手順で、各抗体クローンのマウスコラーゲン抗体誘導関節炎に対する薬効を評価することができる。
抗体の可変領域について、アミノ酸置換等の改変を行うことにより、親和性や特異性が向上或いは変化した例は数多く報告されている。得られた抗体が十分な親和性や特異性を有していない場合、当該抗体についても、例えば以下のようにして親和性や特異性を向上させることは可能と思われる。
クローンMA9-413のVH鎖のアミノ酸配列を配列番号1に示した。当該VH鎖のCDR1~3のアミノ酸配列を配列番号2~4に示した。すなわち、配列番号1に示すVH鎖のアミノ酸配列において、31番目~35番目のアミノ酸配列がCDR1(配列番号2)、50番目~66番目のアミノ酸配列がCDR2(配列番号3)、99番目~115番目のアミノ酸配列がCDR3(配列番号4)に対応している。また、当該VH鎖をコードする遺伝子の塩基配列を配列番号5に示した。
また、クローンMA9-413のVL鎖のアミノ酸配列を配列番号6に示した。当該VL鎖のCDR1~3のアミノ酸配列を配列番号7~9に示した。すなわち、配列番号6に示すVL鎖のアミノ酸配列において、23番目~35番目のアミノ酸配列がCDR1(配列番号7)、51番目~57番目のアミノ酸配列がCDR2(配列番号8)、90番目~96番目のアミノ酸配列がCDR3(配列番号9)に対応している。また、当該VL鎖をコードする遺伝子の塩基配列を配列番号10に示した。
クローンMA9-418のVH鎖のアミノ酸配列を配列番号12に示した。当該VH鎖のCDR1~3のアミノ酸配列を配列番号13~15に示した。すなわち、配列番号12に示すVH鎖のアミノ酸配列において、31番目~35番目のアミノ酸配列がCDR1(配列番号13)、50番目~66番目のアミノ酸配列がCDR2(配列番号14)、99番目~115番目のアミノ酸配列がCDR3(配列番号15)に対応している。また、当該VH鎖をコードする遺伝子の塩基配列を配列番号16に示した。
また、クローンMA9-418のVL鎖のアミノ酸配列は、クローンMA9-413のVL鎖と同一である(配列番号6)。
クローンMA9-107のVH鎖のアミノ酸配列を配列番号18に示した。当該VH鎖のCDR1~3のアミノ酸配列を配列番号19~21に示した。すなわち、配列番号18に示すVH鎖のアミノ酸配列において、31番目~35番目のアミノ酸配列がCDR1(配列番号19)、50番目~66番目のアミノ酸配列がCDR2(配列番号20)、99番目~115番目のアミノ酸配列がCDR3(配列番号21)に対応している。また、当該VH鎖をコードする遺伝子の塩基配列を配列番号22に示した。
また、クローンMA9-107のVL鎖のアミノ酸配列は、クローンMA9-413のVL鎖と同一である(配列番号6)。
クローンHA9-143のVH鎖のアミノ酸配列を配列番号24に示した。当該VH鎖のCDR1~3のアミノ酸配列を配列番号25~27に示した。すなわち、配列番号24に示すVH鎖のアミノ酸配列において、31番目~35番目のアミノ酸配列がCDR1(配列番号25)、50番目~66番目のアミノ酸配列がCDR2(配列番号26)、99番目~115番目のアミノ酸配列がCDR3(配列番号27)に対応している。また、当該VH鎖をコードする遺伝子の塩基配列を配列番号28に示した。
また、クローンHA9-143のVL鎖のアミノ酸配列は、クローンMA9-413のVL鎖と同一である(配列番号6)。
クローンHA9-212のVH鎖のアミノ酸配列を配列番号30に示した。当該VH鎖のCDR1~3のアミノ酸配列を配列番号31~33に示した。すなわち、配列番号30に示すVH鎖のアミノ酸配列において、31番目~35番目のアミノ酸配列がCDR1(配列番号31)、50番目~66番目のアミノ酸配列がCDR2(配列番号32)、99番目~115番目のアミノ酸配列がCDR3(配列番号33)に対応している。また、当該VH鎖をコードする遺伝子の塩基配列を配列番号34に示した。
また、クローンHA9-212のVL鎖のアミノ酸配列は、クローンMA9-413のVL鎖と同一である(配列番号6)。
ヒトcDNA libraryを鋳型に用い、ヒトα9インテグリン遺伝子の主要ドメイン領域、及びヒトα5インテグリン遺伝子のシグナル配列領域をクローニングした。ヒトα5インテグリン遺伝子のシグナル配列領域とヒトα9インテグリン遺伝子の主要ドメイン領域を連結し、pcDNA3.1(-)ベクター(Invitrogen)に組み込んだ、ヒトα9発現ベクターを構築した。
マウス脾臓由来cDNAを鋳型に用い、マウスα4インテグリン遺伝子の全長をクローニングし、pcDNA3.1(+)ベクター(Invitrogen)に組み込み、マウスα4発現ベクターを構築した。
これらの各種インテグリン発現細胞を、以降のスクリーニングや評価に使用した。
J. D. Marks ら(J. Mol. Biol., 222: 581-597, 1991)により報告されている方法を参考にし、健常者20名由来末梢血由来リンパ球を出発材料とし、ファージライブラリーを構築した。構築したVH(γ)-Vκ、VH(γ)-Vλ、VH(μ)-Vκ、VH(μ)-Vλの各サブライブラリーはそれぞれ1.1×108、2.1×108、8.4×107、5.3×107クローンの多様性を有すると評価された。
以下の手順でα9に対する特異抗体の作製を行ったが、まずはマウスα9をターゲットとして機能阻害活性を有するモノクローナル抗体を構築し、マウスの病態モデル系を用いて薬効の有無を評価することとした。
まず親株であるCHO細胞を用いて、ファージディスプレイライブラリーのサブトラクションを行った後、CHO/mα9に反応させた。反応は1時間行い、1%BSA/PBSで3回洗浄した。
洗浄後の細胞画分を10mM HClで懸濁し、10分間インキュベートしてファージを溶出させた。溶出液を1M Tris-HCl (pH7.5)と混ぜて中和した後、TG1に感染させ、ファージを増幅させた。
このパンニングを4round行い、マウスα9に特異的に反応するファージクローンMA9-413を単離した。
MA9-413ファージ抗体のα9に対する反応性をCell ELISAにより解析した。
96ウェルプレート(costar)にCHO/mα9及びCHOを2×104cells/100μL/wellで播種し、37℃、5%CO2で一晩培養した。培地を吸引し、PBSで洗浄した後、1%BSA/PBSで希釈したファージ抗体を反応させた。検出は、西洋わさびペルオキシダーゼ(HRP)標識抗M13抗体(Amersham)とTMB(SIGMA)を組み合わせて行った。波長450nm及び650nmにおける吸光度を、マイクロプレートリーダー(Molecular Devices)を用いて測定した。その結果を図1に示す。MA9-413のα9特異的な反応性が確認されたため、以降の解析を行った。
単離したクローンのscFv遺伝子のVH及びVLのDNA塩基配列をCEQ DTCS Quick Start Kit(BECKMAN COULTER)を用いて決定した。得られたDNA塩基配列の情報をもとに、アミノ酸配列を推定した。
特異クローンMA9-413からプラスミドDNAを回収して、常法に従って大腸菌JM83を形質転換した。この大腸菌を2%グルコース及び100μg/mLのアンピシリンを含む2×YT培地で一夜前培養を行い、2%グルコース及び100μg/mLのアンピシリンを含むSB培地に一部移植して本培養を行った。対数増殖期に終濃度1mMになるようにIPTGを添加し、3時間培養してscFvの発現誘導を行った。培養終了後菌体を遠心回収し、20%Sucrose及び10mM EDTAを含む100mM Tris-HCl溶液(pH7.4)に懸濁して氷中で30分菌体を静置した。次いで8,900×gで30分間遠心し、上清を回収して0.45μmフィルター濾過後に得られた画分をペリプラズム画分とした。これを出発材料とし、SPカラムクロマトグラフィー(Amersham)またはRPAS Purification Module(Amersham)で常法に従ってscFvを精製し、得られた溶出画分をPBSで透析してscFv精製標品とした。
実施例6で調製したscFv精製品について、α9に対する反応性をCell ELISAにより解析した。検出にはHRP標識抗Etag抗体(Amersham)を用い、その他は実施例4と同様の条件で行った。その結果、図2に示すように、濃度依存的かつ特異的な反応性が確認された。
MA9-413 scFvがα9依存性の細胞接着を阻害しうるかを、以下の方法で評価した。
N末OPN改変体(RGD配列をRAAに改変したOPN変異体)をプレートに固定化し、ブロッキングを行った。MA9-413 scFv精製品を添加した後、続けてSW480/mα9を添加し、37℃で1時間インキュベートした。細胞をCrystal violetとメタノールを用いて固定・染色して、洗浄後、接着した細胞中の色素をTriton X-100で抽出し、波長595nmにおける吸光度を測定した。
その結果、図3に示すように、濃度依存的な抑制作用が認められ、MA9-413はマウスα9に対する機能阻害活性を有していることが確認された。
次に、本クローンを二価の抗体にすることで、より機能阻害活性が向上することを期待して、scFv-Fcの分子形態への変換を実施した。MA9-413のscFv遺伝子領域をPCR増幅し、マウスFc融合蛋白質発現ベクターのSalIサイト及びBamHIサイトに挿入することにより、図4に示すscFv-Fcの発現ベクターを構築した。本ベクターにおいては、細胞外への分泌発現を促すリーダー配列とscFv遺伝子、及びマウスIgG1のFc領域をコードする遺伝子が連結されており、その発現はCAGプロモーターにより制御されている。また本ベクターは、薬剤耐性遺伝子として、ネオマイシン耐性遺伝子とアンピシリン耐性遺伝子とを有している。
Lipofectamine 2000(Invitrogen)を用いて、構築したscFv-Fc発現ベクターをCHO-DG44株に遺伝子導入した。500μg/mLのネオマイシンと10%ウシ血清を含むα-MEM培地(Invitrogen)またはEX-CELL302培地(ニチレイバイオサイエンス)で培養を行い、培養上清を回収した。常法に従ってProtein Aカラムクロマトグラフィーでアフィニティー精製を行い、PBSで透析を行った。得られたscFv-Fc溶液を精製標品とした。
MA9-413 scFv-Fcのマウスα9及びヒトα9に対する反応性をCell ELISAにより解析した。抗原にはSW480/mα9、SW480/hα9及びSW480を、希釈液には5%FBSを含む1%BSA/PBSを、検出にはHRP標識抗マウスIgG抗体(ZYMED)を用い、その他は実施例4と同様の条件で行った。その結果、図5に示すように、マウスα9及びヒトα9に対する濃度依存的かつ特異的な反応性が確認された。一方、コントロールとして評価したY9A2抗体は、ヒトα9には反応したがマウスα9には全く反応性を示さなかった。この結果より、MA9-413はマウスα9とヒトα9のいずれをも認識しうるという、これまでに報告例のない新規な反応性を有する抗体クローンであることが確認された。
さらに、MA9-413 scFv-Fcの反応性についてフローサイトメトリーによる評価を行った。
MA9-413 scFv-FcをSW480、SW480/mα9及びSW480/hα9のそれぞれに対して反応させ、フローサイトメトリー解析を行ったところ、マウスα9及びヒトα9に対する反応性が確認された。また、CHO及びCHO/mα4のそれぞれに対しても同様にして反応性を評価したが、マウスα4に対する反応性は確認されなかった(図6)。これらの結果から、MA9-413 scFv-Fcはマウス及びヒトのα9に対して高い特異性をもって反応していることが確かめられた。
MA9-413 scFv-Fcがマウスα9及びヒトα9依存性の細胞接着を阻害しうるかを評価した。
まず、リガンドがOPNの場合の細胞接着について、SW480/mα9またはSW480/hα9を用い、その他は実施例8と同様の条件で行った。
また、リガンドがVCAM-1の場合の細胞接着について、以下の方法で評価した。
マウスVCAM-1/Fcをプレートに固定化し、ブロッキングを行った。細胞はSW480/mα9を用い、その他は実施例8と同様の条件で行った。
その結果、図7に示すように、いずれにおいても濃度依存的な抑制作用が認められ、MA9-413はマウスα9及びヒトのα9に対して機能阻害活性を有し、またリガンドがOPNの場合もVCAM-1の場合も同様に作用しうることが示された。
マウスα9及びヒトα9のいずれにも反応性を有し、いずれに対しても機能阻害活性を示すという、これまでに報告例のない性状を有するMA9-413について、エピトープを同定することを目的として、以下の解析を行った。
インテグリンファミリーのα鎖に共通する特徴として、細胞外領域N末端部分に位置するβプロペラドメインが、リガンドとの相互作用部位であると言われている(Science, 296, 151-155, 2002)。そこでまず、中和エピトープはこの領域内に存在するという仮説を立てた。
反応パターンのみならず、エピトープも新規な領域であることが分かったMA9-413のscFv-Fcについて、マウス関節炎モデルに対して薬効を示しうるかを検討した。
まず、代表的な関節炎モデルの一つであるマウスコラーゲン抗体誘導関節炎に対する効果を調べた。抗コラーゲン抗体カクテルをマウスに投与して、3日後にLPSを投与することにより、関節炎の発症を誘導した。LPS投与の当日と3日後に、MA9-413 scFv-Fcを500、170、56μg/headで、コントロールマウス抗体を500μg/headで腹腔内投与した(各群4~8匹ずつ)。継時的にマウス全肢の腫脹の程度を観察・スコア化し、各群の平均値の推移をグラフ化したものを図11に示した。その結果、MA9-413 scFv-Fcの濃度依存的な関節炎抑制効果が認められた。500μg/head投与群の6日目のスコアにおいては、ポジティブコントロール群のプレドニゾロン投与群とほぼ同等にまで抑制されており、十分に強い薬効つまり抗炎症作用を有することが確認された。
次に、もう一つの代表的な関節炎モデルであるマウスコラーゲン誘導関節炎に対してもMA9-413 scFv-Fcが薬効を示すかを評価した。実施例15のコラーゲン抗体誘導関節炎では急性期の炎症反応が惹起されるのに対し、コラーゲン誘導関節炎では慢性的な炎症応答が引き起こされることが知られている。
ウシII型コラーゲンを3週間隔で2回マウスに投与することにより、関節炎の発症を誘導した。2回目の投与の4日後、6日後、8日後、10日後及び12日後にMA9-413 scFv-Fcを500、170、56μg/headで、コントロールマウス抗体を500μg/headで、ポジティブコントロールとしてエタネルセプトを500、150μg/headで腹腔内投与した(各群10匹ずつ)。継時的にマウス全肢の腫脹の程度を観察・スコア化し、各群の平均値の推移をグラフ化したものを図12に示した。その結果、MA9-413 scFv-Fcの濃度依存的な関節炎抑制効果が認められた。500μg/head投与群においては、ポジティブコントロール群のエタネルセプト500μg/head投与群を上回る抑制効果であり、十分に強い薬効を有することが確かめられた。
さらに、関節炎モデルにおける破骨細胞分化に対する効果を調べた。上記実施例15で使用したマウスコラーゲン抗体誘導関節炎において、関節炎を惹起するLPSの投与翌日のマウスの大腿骨より骨髄細胞を採取し、RANKL(最終濃度30ng/mL)およびM-CSF(最終濃度100ng/mL)を含んだαMEM培地にて培養することにより破骨細胞の分化を誘導した。培養交換は開始後3日目に1度行った。培養開始後7日目にTRAP(酒石酸抵抗性酸フォスファターゼ)染色を行い、染色された細胞を破骨細胞として細胞数を計測した。なお、ネガティブコントロールとして、抗HBs抗体を使用した。その結果、関節炎を誘導したマウスの骨髄細胞にMA9-413を2μg/mL加えておくと破骨細胞への分化を強く抑制した(図13上)。また、LPS投与と同時にマウスにMA9-413 250μg/headを静脈内投与した翌日に採取した骨髄細胞を用いた場合においても破骨細胞の分化を抑制した(図13下)。
MA9-413はヒトα9よりもマウスα9に強く反応する抗体であるため、ヒトの関節炎への適用を目指すには、親和性が十分でない可能性が考えられる。そこで、MA9-413の分子改変による親和性の向上を試みた。多くの場合、抗体可変領域の内、抗原認識に最も強く寄与しているのはVHのCDR3領域である。MA9-413のVHのCDR3の配列は配列番号4に示した通りであるが、Tyrのクラスターが特徴的に配置されている。本クローンの可変領域について立体構造モデルを作製し解析した結果、108番目のTyr及び109番目のTyrが特に抗原結合面において突出して配置されている可能性が見出された。そこで、これらのTyrの抗原認識における役割を評価するため、108番目のTyrをAlaに置換した改変体scFv(以後、MA9-418と呼ぶ)及び109番目のTyrをAlaに置換した改変体scFv(以後、MA9-419と呼ぶ)の発現ベクターを、site-directed mutagenesis法により構築した。
それらのクローンについて実施例5と同様にDNA塩基配列を解析し、アミノ酸配列を推定した。クローンの配列を図14に示す。
上記のクローンMA9-418、HA9-107、HA9-143及びHA9-212について、プラスミドDNAの宿主を大腸菌株JM83に変えて、scFvの発現と精製を行った。大腸菌形質転換体を2%グルコース及び100μg/mLのアンピシリンを含む2×YT培地で培養を行い、対数増殖期に終濃度1mMになるようにIPTGを添加して一夜培養することにより、scFvの発現を誘導した。培養終了後菌体を回収し、20%Sucrose及び10mM EDTAを含む100mM Tris-HCl溶液(pH7.4)に懸濁して氷中で30分菌体を静置した。次いで8,900×gで30分間遠心し、上清を回収して0.45μmフィルター濾過後に得られた画分をペリプラズム画分とした。これを出発材料とし、RPASPurification Module(Amersham)で常法に従ってscFvを精製し、得られた溶出画分をPBSで透析してscFv精製標品とした。
MA9-418、HA9-107、HA9-143及びHA9-212についてscFv-Fc遺伝子の構築を、実施例9と同様にして行った。
scFv-Fcの発現は、フリースタイル293-F細胞(Invitrogen)を宿主とした一過性発現により行った。293フェクチン試薬(Invitrogen)を用いて遺伝子導入を行い、フリースタイル293発現培地(Invitrogen)で2~3日培養後、培養上清を遠心及び0.22μmフィルター濾過により回収した。
精製はProtein Aカラムクロマトグラフィーを用いて常法に従って行った。PBS透析後に得られたscFv-Fc溶液を精製標品とした。
調製したscFv-Fc精製品のマウスα9及びヒトα9に対する反応性を、実施例11と同様にCell ELISAにより解析した。その結果、図16に示すように、MA9-413に比べてMA9-418、HA9-107、HA9-143及びHA9-212はヒトα9に対する反応性が向上していた。
MA9-418、HA9-107、HA9-143及びHA9-212がMA9-413と同様にα9のL1領域を認識しているかどうかを調べるために、以下の検討を行った。MA9-413のファージ抗体を一定濃度にして、実施例4と同様に行ったCell ELISAにおいて、各改変体のscFv-Fcを段階希釈してサンプルと同時に添加することにより、MA9-413のファージ抗体に対して競合阻害がかかるか否かを評価した。その結果、図17に示すように、濃度依存的に競合阻害がかかることが確認された。よって、MA9-418、HA9-107、HA9-143及びHA9-212についてもMA9-413と同様にα9のL1領域を認識していることが強く示唆された。
各改変体クローンのscFv-Fcについて、ヒトα9及びマウスα9依存性の細胞接着に対する阻害能を、実施例13と同様に評価した。表1にIC50値をまとめた。いずれの改変体クローンも、オリジナルのMA9-413と比較して、ヒトα9に対して強い阻害能を有することが確かめられた。特に、HA9-212については、MA9-413と比較して、約1000倍のヒトα9に対する阻害能を有していた。
ヒトα9に対して最も高い反応性を示したクローンHA9-212について、IgGの分子形態における反応性を検討した。IgGの遺伝子構築は以下の手順で行った。まず、HA9-212のVH遺伝子領域をPCR増幅し、ヒトH鎖発現ベクターのクローニングサイトに挿入した。本ベクターにおいては、細胞外への分泌発現を促すリーダー配列とVH遺伝子、及びヒトIgG1定常領域の遺伝子が連結されており、その発現はCAGプロモーターにより制御されている。また本ベクターは、薬剤耐性遺伝子として、ネオマイシン耐性遺伝子とアンピシリン耐性遺伝子とを有している。次に、MA9-212のVL遺伝子領域をPCR増幅し、ヒトL鎖発現ベクターのクローニングサイトに挿入した。本ベクターにおいては、細胞外への分泌発現を促すリーダー配列とVL遺伝子、及びヒトκ鎖定常領域の遺伝子が連結されており、その発現はCAGプロモーターにより制御されている。また本ベクターは、dhfr遺伝子とアンピシリン耐性遺伝子とを有している。
IgGの発現は、COS-7細胞及びフリースタイル293-F細胞(Invitrogen)を宿主とした一過性発現により行った。COS-7細胞に対してはLipofectamine2000(Invitrogen)を用いて、フリースタイル293-F細胞に対しては293フェクチン試薬(Invitrogen)を用いて遺伝子導入を行い、2~3日培養後、培養上清を遠心及び0.22μmフィルター濾過により回収した。
培養上清中のIgG発現量をヒトIgG定量ELISAにより定量し、各IgG濃度におけるヒトα9及びマウスα9に対する反応性をCell ELISAにより解析した。検出にはHRP標識抗ヒトIgG(Fc)抗体(American Qualex)を用い、その他は実施例11と同様の条件で行った。その結果、図18に示すように、ヒトα9及びマウスα9に対する濃度依存的かつ特異的な反応性が確認され、特にヒトα9に対しては強い反応性を示した。この結果より、HA9-212はIgGの分子形態においてもα9に対する反応性を示すことが確認された。
本出願は、日本で出願された特願2007-340203(出願日:平成19年12月28日)を基礎としており、その内容はすべて本明細書に包含されるものとする。
Claims (16)
- ヒトα9インテグリン及びマウスα9インテグリンを認識し、該α9インテグリンとそれらのリガンドとの相互作用を阻害する、ヒト抗α9インテグリン抗体または抗体フラグメント。
- ヒトα9インテグリン(配列番号36)の104番目のArgから122番目のAspまでの領域が主として構成するエピトープ、及びマウスα9インテグリン(配列番号37)の105番目のArgから123番目のAspまでの領域が主として構成するエピトープを認識する、請求項1に記載の抗体または抗体フラグメント。
- 以下の配列番号に各々示されるアミノ酸配列からなる(a)重鎖相補性決定領域及び(b)軽鎖相補性決定領域(CDR1、CDR2、CDR3)を有する、請求項1または2に記載の抗体または抗体フラグメント。
(a)重鎖相補性決定領域CDR1、CDR2、CDR3
配列番号2、配列番号3、配列番号4;
配列番号13、配列番号14、配列番号15;
配列番号19、配列番号20、配列番号21;
配列番号25、配列番号26、配列番号27;または
配列番号31、配列番号32、配列番号33;
(b)軽鎖相補性決定領域CDR1、CDR2、CDR3
配列番号7、配列番号8、配列番号9 - 配列番号31、配列番号32、配列番号33に各々示されるアミノ酸配列からなる重鎖相補性決定領域CDR1、CDR2、CDR3を有する、請求項3に記載の抗体または抗体フラグメント。
- 配列番号1、配列番号12、配列番号18、配列番号24、配列番号30のいずれかに示されるアミノ酸配列からなる重鎖可変領域、及び配列番号6に示されるアミノ酸配列からなる軽鎖可変領域を有する、請求項1または2に記載の抗体または抗体フラグメント。
- 配列番号30に示されるアミノ酸配列からなる重鎖可変領域を有する、請求項5に記載の抗体または抗体フラグメント。
- 当該抗体が、完全抗体である請求項1から6のいずれかに記載のヒト抗α9インテグリン抗体。
- 当該抗体フラグメントが、scFvまたはscFv-Fcである請求項1から6のいずれかに記載のヒト抗α9インテグリン抗体フラグメント。
- 請求項1から8のいずれかに記載の抗体または抗体フラグメントをコードする遺伝子。
- 請求項9に記載の遺伝子を含む組換え発現ベクター。
- 請求項9に記載の遺伝子が導入された形質転換体。
- 請求項9に記載の遺伝子を宿主に発現させることによって、ヒト抗α9インテグリン抗体または抗体フラグメントを生産する方法。
- 請求項1から8のいずれかに記載の抗体または抗体フラグメントを含む、関節リウマチの予防または治療剤。
- 請求項1から8のいずれかに記載の抗体または抗体フラグメントの治療有効量を対象に投与する工程を包含する、当該対象における関節リウマチを予防または治療する方法。
- 関節リウマチの予防または治療剤の製造における、請求項1から8のいずれかに記載の抗体または抗体フラグメントの使用。
- 関節リウマチを予防または治療するための、請求項1から8のいずれかに記載の抗体または抗体フラグメント。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/810,939 US8715655B2 (en) | 2007-12-28 | 2008-12-26 | Human anti-α9 integrin antibody |
ES08867627.5T ES2582277T3 (es) | 2007-12-28 | 2008-12-26 | Anticuerpo anti-integrina alfa 9 de ser humano |
EP08867627.5A EP2236605B1 (en) | 2007-12-28 | 2008-12-26 | Human anti-alpha 9 integrin antibody |
JP2009548111A JP5371779B2 (ja) | 2007-12-28 | 2008-12-26 | ヒト抗α9インテグリン抗体 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007340203 | 2007-12-28 | ||
JP2007-340203 | 2007-12-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009084671A1 true WO2009084671A1 (ja) | 2009-07-09 |
Family
ID=40824384
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/073825 WO2009084671A1 (ja) | 2007-12-28 | 2008-12-26 | ヒト抗α9インテグリン抗体 |
Country Status (5)
Country | Link |
---|---|
US (1) | US8715655B2 (ja) |
EP (1) | EP2236605B1 (ja) |
JP (1) | JP5371779B2 (ja) |
ES (1) | ES2582277T3 (ja) |
WO (1) | WO2009084671A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011004847A1 (ja) * | 2009-07-07 | 2011-01-13 | 一般財団法人化学及血清療法研究所 | 新規ヒト化抗ヒトα9インテグリン抗体 |
WO2019230823A1 (ja) * | 2018-05-30 | 2019-12-05 | 株式会社Cоgnanо | 抗体を取得する方法、抗体の特定方法、抗体の製造方法、及び抗体 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2753280C (en) * | 2009-02-23 | 2017-04-25 | Gene Techno Science Co., Ltd. | Anti-human .alpha.9 integrin antibody and use thereof |
WO2022082030A2 (en) * | 2020-10-15 | 2022-04-21 | Gritstone Bio, Inc. | Antigen-binding proteins and related methods of use |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006075784A1 (ja) | 2005-01-13 | 2006-07-20 | Gene Techno Science Co., Ltd. | 抗α9インテグリン抗体とその用途 |
WO2008007804A1 (fr) * | 2006-07-12 | 2008-01-17 | Gene Techno Science Co., Ltd. | ANTICORPS ANTI-INTÉGRINE α-9 HUMAINE ET UTILISATION DE CELUI-CI |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6939855B2 (en) | 1997-07-31 | 2005-09-06 | Elan Pharmaceuticals, Inc. | Anti-inflammatory compositions and method |
US7396913B2 (en) * | 2002-10-14 | 2008-07-08 | Abbott Laboratories | Erythropoietin receptor binding antibodies |
TWI362940B (en) | 2005-03-31 | 2012-05-01 | Gen Hospital Corp | A use of agonist and/or antagonist of hgf/hgfr activity |
-
2008
- 2008-12-26 WO PCT/JP2008/073825 patent/WO2009084671A1/ja active Application Filing
- 2008-12-26 ES ES08867627.5T patent/ES2582277T3/es active Active
- 2008-12-26 JP JP2009548111A patent/JP5371779B2/ja not_active Expired - Fee Related
- 2008-12-26 EP EP08867627.5A patent/EP2236605B1/en not_active Not-in-force
- 2008-12-26 US US12/810,939 patent/US8715655B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006075784A1 (ja) | 2005-01-13 | 2006-07-20 | Gene Techno Science Co., Ltd. | 抗α9インテグリン抗体とその用途 |
WO2008007804A1 (fr) * | 2006-07-12 | 2008-01-17 | Gene Techno Science Co., Ltd. | ANTICORPS ANTI-INTÉGRINE α-9 HUMAINE ET UTILISATION DE CELUI-CI |
Non-Patent Citations (19)
Title |
---|
AM. J. RESPIR. CELL MOL. BIOL., vol. 15, 1996, pages 664 - 672 |
BOSTIAN, PROC. NATLA ACAD. SCI. USA, vol. 77, 1980, pages 4505 |
CURRENT PROTOCOLS IN MOLECULAR BIOLOGY EDIT., vol. 5, no. 8, 1987, pages 1 - 8 |
J. AM. MED. ASSOC., vol. 199, 1967, pages 519 |
J. BACTERIO., vol. R1987, no. 169, pages 4379 - 4383 |
J. D. MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581 - 597 |
JOURNAL OF BONE AND MINERAL RESEARCH, vol. 21, 2006, pages 1657 - 1665 |
NIWA H. ET AL., GENE, vol. 108, 1991, pages 193 - 200 |
PCR METHODS AND APPLICATIONS, vol. 2, 1992, pages 28 - 33 |
PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 8404 |
PROC. NATL. ACAD. SCI. USA, vol. 94, 1997, pages 65 - 72 |
PROC. NATL. ACAD. SCI. USA, vol. 94, 1997, pages 7198 - 7203 |
PROC. SOC. EXP. BIOL. MED., vol. 73, 1950, pages 1 |
SCIENCE, vol. 122, 1952, pages 501 |
SCIENCE, vol. 296, 2002, pages 151 - 155 |
See also references of EP2236605A4 * |
THE JOURNAL OF CLINICAL INVESTIGATION, vol. 115, 2005, pages 1060 - 1067 |
VIROLOGY, vol. 8, 1959, pages 396 |
WANG A. ET AL.: "Differential regulation of airway epithelial integrins by growth factors.", AM. J. RESPIR. CELL MOL. BIOL., vol. 15, no. 5, 1996, pages 664 - 672, XP002915231 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011004847A1 (ja) * | 2009-07-07 | 2011-01-13 | 一般財団法人化学及血清療法研究所 | 新規ヒト化抗ヒトα9インテグリン抗体 |
WO2019230823A1 (ja) * | 2018-05-30 | 2019-12-05 | 株式会社Cоgnanо | 抗体を取得する方法、抗体の特定方法、抗体の製造方法、及び抗体 |
JPWO2019230823A1 (ja) * | 2018-05-30 | 2021-07-08 | 株式会社Cognano | 抗体を取得する方法、抗体の特定方法、抗体の製造方法、及び抗体 |
Also Published As
Publication number | Publication date |
---|---|
US20110014213A1 (en) | 2011-01-20 |
US8715655B2 (en) | 2014-05-06 |
EP2236605B1 (en) | 2016-06-08 |
EP2236605A4 (en) | 2012-08-15 |
JPWO2009084671A1 (ja) | 2011-05-19 |
JP5371779B2 (ja) | 2013-12-18 |
ES2582277T3 (es) | 2016-09-12 |
EP2236605A1 (en) | 2010-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102330596B1 (ko) | 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도 | |
JP5982698B2 (ja) | Dll4に特異的に結合する新規モノクローナル抗体及びその用途 | |
US7763249B2 (en) | Human anti-amyloid β peptide antibody and fragment of said antibody | |
EP3174903B1 (en) | Bispecific single chain antibody construct with enhanced tissue distribution | |
CN106999587B (zh) | 多价中间表位,中间表位结合抗体及其用途 | |
CN107614529A (zh) | Pd‑l1抗体、其抗原结合片段及其医药用途 | |
TW201609812A (zh) | 最佳化之跨物種特異性雙特異性單鏈抗體構築體 | |
CN109843927A (zh) | 抗b7-h3抗体、其抗原结合片段及其医药用途 | |
JP2020188765A (ja) | Lox1特異的結合タンパク質及びその使用 | |
US11248048B2 (en) | Antibody to programmed cell death 1 (PD-1) and use thereof | |
CN101389791A (zh) | 融合蛋白文库的产生和筛选方法及其应用 | |
WO2022194201A1 (zh) | 一种靶向cldn18.2的抗体或其抗原结合片段及其应用 | |
JP5371779B2 (ja) | ヒト抗α9インテグリン抗体 | |
JP2022527372A (ja) | 抗インテグリン抗体及びそれらの使用 | |
JP7433222B2 (ja) | Alk7結合タンパク質およびその使用 | |
AU2017230091A1 (en) | Activin type 2 receptor binding proteins and uses thereof | |
JP5440179B2 (ja) | 改良型ヒト化抗ヒトα9インテグリン抗体 | |
EP2821416B1 (en) | Novel anti-human il-23 receptor antibody | |
CA3152959A1 (en) | Anti-cxcr2 antibodies and uses thereof | |
WO2011004847A1 (ja) | 新規ヒト化抗ヒトα9インテグリン抗体 | |
CN115947855B (zh) | 抗cd24抗体的制备及其用途 | |
JP7432716B2 (ja) | ヒト4-1bbに結合可能な分子及びその応用 | |
EP3960763A2 (en) | Anti-tie2 antibody and use thereof | |
JP6440968B2 (ja) | IgSF4/TSLC1/CADM1を特異的に認識できる抗体 | |
AU2021416127A1 (en) | Pd-1 binding molecule and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08867627 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2009548111 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008867627 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12810939 Country of ref document: US |